Full-Time

Senior Manager

Gxp Quality

Confirmed live in the last 24 hours

Tango Therapeutics

Tango Therapeutics

51-200 employees

Develops targeted cancer therapies using synthetic lethality

Biotechnology
Healthcare

Senior

Boston, MA, USA

Office located at 201 Brookline Avenue, Fenway area, Boston, Massachusetts.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s Degree in a scientific discipline; advanced degree preferred
  • At least 7 years in the pharmaceutical industry with 5 years in GCP QA
  • Solid understanding of regulations and guidance for GCP, GLP, and GVP
  • Experience with US and international clinical studies
  • Excellent verbal and written communication skills
  • Experience reviewing clinical documents
  • Good organizational skills and ability to work independently
  • Collaborative problem-solver
  • Able to travel domestically and internationally approximately 25% of the time
Responsibilities
  • You will provide GCP/GLP/GVP QA oversight and support to cross functional stakeholders
  • Support development of the annual GCP/GLP/GVP audit schedule
  • Conduct and/or oversee GCP/GLP/GVP audits through closure as per the annual audit schedule, to include clinical investigator sites, CROs/vendors, process, system, study project, and document audits, to assure compliance with global regulations, guidance, and internal procedures
  • Track and effectively communicate deviation and audit trends to stakeholders
  • Identify, investigate, escalate, track, and resolve quality issues both internally and externally
  • Liaise with QA counterpart at CROs and vendors
  • Assist in preparing for, and hosting regulatory inspections with cross functional stakeholders
  • Conduct QA review of GCP protocols, ICFs, CSRs, and other clinical trial specific documents
  • Conduct QA review of GLP reports and validation plans
  • Additional duties and responsibilities as required

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of just one does not. This method enables them to create more effective therapies for cancer patients. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies interested in advanced cancer therapies. They collaborate with larger pharmaceutical firms, like Gilead Sciences, to co-develop their treatments, which helps them secure funding and speed up the development process. Tango's goal is to bring next-generation targeted immunotherapies to market, supported by a strong team and strategic partnerships.

Company Stage

IPO

Total Funding

$341.4M

Headquarters

Cambridge, Massachusetts

Founded

2017

Growth & Insights
Headcount

6 month growth

1%

1 year growth

17%

2 year growth

87%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking aligns with Tango's precision oncology focus, expediting approvals.
  • Growing interest in synthetic lethality boosts collaboration opportunities for Tango.
  • Rise of personalized medicine increases demand for Tango's targeted therapies.

What critics are saying

  • Discontinuation of TNG348 due to liver toxicity may impact investor confidence.
  • Reliance on partnerships like Gilead poses risks if altered or terminated.
  • Intensifying competition in precision oncology could affect Tango's market share.

What makes Tango Therapeutics unique

  • Tango leverages synthetic lethality to target cancer cells while sparing healthy ones.
  • Their focus on tumor suppressor gene loss is a novel approach in oncology.
  • Collaboration with Gilead Sciences accelerates development and commercialization of therapies.

Help us improve and share your feedback! Did you find this helpful?